

A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies

NCT05356182

Status	RECRUITING
Phase	Not Applicable
Sponsor	State University of New York at Buffalo
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (13)

- Histologically documented solid tumor malignancies which is amenable for immunotherapy treatment with immune checkpoint inhibitors (i.e. PD1, PD-L1, CTLA inhibitors) as single agents or in combination.
- Metastatic disease as evidenced by soft tissue and/or bony metastases on baseline bone scan and/or computed tomography (CT) scan of the chest, abdomen, and pelvis
- Life expectancy of at least 6 months
- Adults ≥ 18 years of age
- Adequate hematologic, renal, and liver function as evidenced by the following:
... and 8 more (see full listing online)

Exclusion (8)

- Eastern Cooperative Oncology Group (ECOG) performance status 2 or higher
- Treatment with any of the following medications or interventions within 28 days of registration:
- Systemic corticosteroids; however, use of inhaled, intranasal, and topical steroids is acceptable.
- High dose calcitriol $[1,25(\text{OH})_2\text{VitD}]$ (i.e., $> 7.0 \mu\text{g}/\text{week}$)
- A requirement for systemic immunosuppressive therapy for any reason
... and 3 more (see full listing online)

Locations (1 total)

University at Buffalo / Great Lakes Cancer Care, Buffalo, New York, United States